- Leclerc, Sainz lament 'disappointing' Saturday in Singapore
- Bottega Veneta holds investors' aces as Madonna pops into D&G
- Beirut digs for victims at building flattened in Israeli strike
- Verstappen stages protest over 'ridiculous' swearing punishment
- Bayern boss Kompany lauds 'special talent' Olise
- Diaz fires Liverpool top of Premier League, Spurs bounce back
- Heavy fire over Israel-Lebanon border after deadly Beirut strike
- Ramos guides unbeaten Toulouse to Montpellier win despite Hogg scuffle
- Myanmar flood death toll jumps to 384
- Chelsea owners 'happy' with win at West Ham amid rift report
- Kane and Olise run riot as Bayern thump Bremen
- Ramos guides unbeaten Toulouse to Montpellier win
- Norris pips Verstappen to dramatic Singapore pole after Sainz crash
- Carey takes Australia to 270 in 2nd ODI against England after collapse
- Two Hezbollah leaders killed in Israel's Beirut strike
- Hungary Danube waters reach decade high after Storm Boris
- Bagnaia cuts Martin's MotoGP lead with Emilia-Romagna sprint win
- Jackson double fires Chelsea to victory at woeful West Ham
- Fiji beat Japan to lift Pacific Nations Cup
- Kasatkina to face Haddad Maia in Korea Open final
- S.Africa snowfall closes roads, strands motorists overnight
- Lawyers of women alleging Al-Fayed sex abuse receive over 150 new enquiries
- President Museveni's son backs Ugandan strongman for 7th term
- Norris quickest as Verstappen bounces back in Singapore practice
- Wallabies lament All Blacks' fast start
- Germany's Oktoberfest opens under tight security after attacks
- Environmental protesters block French cruise liner port
- Hezbollah in disarray after Israeli strike kills top commanders
- No place like home: Biden hosts 'Quad' leaders
- One dead, 7 missing as heavy rains trigger floods in central Japan
- Zelensky says no UK, US go-ahead to use long-range missiles
- New Zealand edge Australia 31-28 in Bledisloe Cup thriller
- Japan orders evacuations as heavy rains trigger floods in quake-hit area
- New Zealand pilot freed in Indonesia after 19 months in rebel captivity
- Hezbollah in disarray after Israeli air strike kills top commanders
- The BYD Seal Hybrid U DM-i AWD in a practical test by journalists
- Leading climate activist released from Vietnam jail
- Ethiopians struggle with bitter pill of currency reform
- Sri Lanka votes in first poll since economic collapse
- Feminist author warns of abortion disaster if Trump wins US election
- US city of Flint still reeling from water crisis, 10 years on
- Arsenal's mean defence faces acid test to shut out Man City again
- Late surge lifts Thailand's Jeeno to LPGA Queen City lead
- DeChambeau says PGA's Ryder Cup decision 'just the start'
- Alcaraz defeated on Laver Cup debut
- Postecoglou embraces 'struggle' to make Spurs a success
- Nice hand 'ashamed' Saint-Etienne 8-0 Ligue 1 mauling
- Boeing CEO says ending strike 'a top priority'
- Stock markets mostly fall after Fed-fueled rally
- Harris slams Trump for hypocrisy on abortion as US starts voting
Mixed results for Moderna mRNA flu vaccine trial
US biotech company Moderna said Thursday it had mixed results from a large-scale trial of its mRNA flu shot, based on the same technology used in its successful Covid-19 vaccine.
Moderna's experimental mRNA-1010 flu shot is "quadrivalent," meaning it targets four strains of flu: A/H1N1, A/H3N2, B/Yamagata and B/Victoria -- selected based on recommendations by the World Health Organization (WHO).
The Massachusetts-based company said that its flu shot generated an immune response against influenza A strains that was equal or superior to that of already licensed vaccines.
However, it fell short of the already approved vaccines against strains of the less-common influenza B, Moderna said in a statement.
"Today's results represent an important step forward in the development of mRNA-based influenza vaccines," Moderna president Stephen Hoge said.
"We have already updated the vaccine that we believe could improve immune responses against influenza B and will seek to quickly confirm those improvements in an upcoming clinical study."
The Phase 3 trial of the mRNA shot involved 6,102 adults in Argentina, Australia, Colombia, Panama, and the Philippines during the Southern Hemisphere influenza season.
Participants received a single dose of mRNA-1010 or a single dose of a licensed influenza vaccine.
Moderna said 70 percent of the mRNA-1010 recipients reported adverse reactions such as headaches, swelling and fatigue compared to 48 percent in the other group.
Virus strains have to be selected six to nine months before the vaccines are intended to be used, and their efficacy is approximately 40 to 60 percent.
Moderna is simultaneously conducting an efficacy trial of its vaccine.
Moderna and other vaccine manufacturers, including Sanofi, hope that mRNA technology -- which provokes an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells -- can accelerate immunization development and production, and heighten efficacy.
There are some three to five million severe influenza cases annually worldwide and between 290,000 and 650,000 deaths, the WHO says.
Moderna's stock price was down more than six percent in after-hours trading in New York.
L.Durand--AMWN